Intervention

Famitinib

ClinicalTrials.gov intervention label

Clinical trials10
Recruiting5
Common conditions19
Lead sponsors shown5

Clinical trials

10 shown
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerNCT06649331 · 2024-10-21
RECRUITING
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabNCT06516289 · 2024-09-30
RECRUITING
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.NCT05760378 · 2023-03-17
RECRUITING
SNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30
RECRUITING
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITING
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT05176080 · 2021-12-08
TERMINATED
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.NCT05005468 · 2021-09-01
UNKNOWN
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaNCT04888429 · 2021-07-19
UNKNOWN
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858 · 2020-05-01
UNKNOWN
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)NCT02356991 · 2014-12-01
SUSPENDED

Common conditions

Breast Cancer4HER2-negative Breast Cancer4Advanced Breast Cancer2Breast Neoplasm2Hormone Receptor Positive Tumor2Metastatic Breast Cancer2BRCA-Mutated Breast Carcinoma1Breast Tumors1Early-stage Breast Cancer1HER2-positive Breast Cancer1Hormone Receptor Negative Tumor1Locally Advanced Breast Cancer1Metastatic Cancer1Non-Small Cell Lung Cancer (NSCLC)1NSCLC1Sarcomatoid Carcinoma of Lung1Triple Negative Breast Cancer (TNBC)1Triple-Negative Breast Cancer1Triple-Negative Breast Cancer (TNBC)1

Trial status mix

RECRUITING5
UNKNOWN3
SUSPENDED1
TERMINATED1

Phase mix

PHASE29
PHASE11
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.